Zusammenfassung
Schmerzen sind ein häufiges Problem für Multiple Sklerose-(MS)-Patienten, das oft gezielt erfragt werden muss. Sie lassen sich unter diagnostischen und therapeutischen Gesichtspunkten in 4 Kategorien einteilen: 1. Schmerzen als direkte Folge einer MS: Schmerzhafte paroxysmale Symptome wie die Trigeminusneuralgie oder schmerzhafte tonische Verkrampfungen der Extremitätenmuskulatur werden mit Carbamazepin als Mittel der ersten Wahl behandelt, Alternativen sind Lamotrigin, Gabapentin, Oxcarbazepin und andere Antikonvulsiva oder auch Misoprostol. Schmerzhafte „brennende” Missempfindungen bzw. Dysästhesien als häufigstes chronisches Schmerzsyndrom sprechen vor allem auf trizyklische Antidepressiva wie Amitriptylin an oder auf Carbamazepin. Alternativen sind Gabapentin und Lamotrigin. In der Eskalation kommen auch Opioide zum Einsatz, der Stellenwert der Cannabinoide ist derzeit noch nicht abschließend zu bewerten. 2. Schmerzen als indirekte Folge der MS: Schmerzhaft einschießende Spastik bessert sich oft unter adäquater Lagerung, medikamentös unter klassischen Antispastika wie Baclofen oder Tizanidin. Eine Alternative ist Gabapentin, in der Eskalation lokal Botulinumtoxin bzw. intrathekal Baclofen. Durch Fehlhaltung bedingte Gelenk- und Muskelschmerzen lassen sich durch Krankengymnastik und physikalische Therapie lindern, Druckläsionen durch optimal angepasste Hilfsmittel vermeiden. 3. Schmerzen durch therapeutische Maßnahmen kommen lokal vor allem bei subkutaner Injektion von β-Interferonen oder Glatiramerazetat vor und lassen sich durch optimale Technik bzw. lokale Kühlung positiv beeinflussen. Die systemischen Interferon-Nebenwirkungen wie Myalgien lassen sich durch Paracetamol oder Ibuprofen reduzieren. 4. Primär MS-unabhängige Schmerzen wie Rücken- oder Kopfschmerzen treten häufig auch bei MS-Betroffenen auf, können durch die Erkrankung jedoch beeinflusst werden. Die Therapie folgt den entsprechenden Leitlinien. Insgesamt wird nach genauer Analyse eines Schmerzes und seines Zusammenhangs mit der MS eine spezifische Therapie nach evidenzbasierten Kriterien möglich, die die Lebensqualität vieler Betroffener bessern hilft.
Abstract
While pain is a common problem in multiple sclerosis (MS) patients, it is frequently overlooked and has to be asked for actively. Pain can be classified into 4 diagnostically and therapeutically relevant categories. 1. pain directly related to MS: Painful paroxysmal symptoms like trigeminal neuralgia or painful tonic spasms are treated with carbamazepine as first choice, or lamotrigine, gabapentin, oxcarbazepine and other anticonvulsants. Painful “burning” dysaesthesias, the most frequent chronic pain syndrome, are treated with tricyclic antidepressants or carbamazepine, further options include gabapentin or lamotrigine. While escalation therapy may require opioids, the role of cannabinoids in the treatment of pain still has to be determined. 2. Pain indirectly related to MS: Pain related to spasticity often improves with adaequate physiotherapy. Drug treatment includes antispastic agents like baclofen or tizanidine, alternatively gabapentin. In severe cases botulinum toxin injections or intrathecal baclofen merit consideration. Physiotherapy and physical therapy may ameliorate malposition-induced joint and muscle pain. Moreover, painful pressure lesions should be avoided using optimally adjusted aids. 3. Treatment-related pain can occur with subcutaneous injections of beta interferons or glatiramer acetate and may be reduced by optimizing the injection technique and by local cooling. Systemic side effects of interferons like myalgias can be reduced by paracetamol or ibuprofen. 4. Pain unrelated to MS such as back pain or headache are frequent in MS patients and may be worsened by the disease. Treatment should be follow established guidelines. In summary, a careful analysis of the pain syndrome will allow the design of the appropriate treatment plan using various medical and non-medical options and thus will help to ameliorate the patients' quality of life.
Literatur
1
Pöllmann W, Feneberg W.
Schmerzen bei Multipler Sklerose - moderne Möglichkeiten der neurologischen Rehabilitation.
Nervenheilkunde.
1999;
18
526-531
2
Fryze W, Zaborski J, Czlonkowska A.
Pain in the course of multiple sclerosis.
Neurol Neurochir Pol.
2002;
36
275-284
3
Ehde D M, Gibbons L E, Chwastiak L, Bombardier C H, Sullivan M D, Kraft G H.
Chronic pain in a large community sample of persons with multiple sclerosis.
Mult Scler.
2003;
9
605-611
4
Stenager E, Knudsen L, Jensen K.
Acute and chronic pain syndromes in multiple sclerosis. A 5-year follow-up study.
Ital J Neurol Sci.
1995;
16
629-632
5
Stenager E, Knudsen L, Jensen K.
Acute and chronic pain syndromes in multiple sclerosis.
Acta Neurol Scand.
1991;
84
197-200
6
Solomon P.
Congruence between health professionals' and patients' pain ratings: a review of the literature.
Scand J Caring Sci.
2001;
15
174-180
7
Pöllmann W, Feneberg W, Erasmus L-P.
Schmerzen bei Multipler Sklerose - ein immer noch unterschätztes Problem.
Nervenarzt.
2004;
75
135-140
8
Brichetto G, Messmer Uccelli M, Mancardi G L, Solaro C.
Symptomatic medication use in multiple sclerosis.
Mult Scler.
2003;
9
458-460
9
Radbruch L, Loick G, Kiencke P, Lindena G, Sabatowski R, Grond S, Lehmann K A, Cleeland C S.
Validation of the German version of the Brief Pain Inventory.
J Pain Symptom Manage..
1999;
18
180-187
10
Stein C, Mendl G.
The German counterpart to McGill pain questionnaire.
Pain.
1988;
32
251-255
11 Merskey H, Bogduk N. (eds) .Classification of chronic pain. 2nd ed. Seattle: IASP Press 1994
12
Headache Classification Committee of the International Headache Society .
The International Classification of Headache Disorders. 2nd ed. Cephalalgia 2004; 24 (suppl. 1): 1 - 160. Kopfschmerzklassifikationskomitee der International Headache Society. Die internationale Klassifikation von Kopfschmerzerkrankungen. 2. Auflage.
Nervenheilkunde.
2003;
22
531-670
13
Beard S, Hunn A, Wight J.
Treatments for spasticity and pain in multiple sclerosis: a systematic review.
Health Technol Assess.
2003;
7
1-124
14
Ferreira P H, Ferreira M L, Maher C G, Refshauge K, Herbert R D, Latimer J.
Effect of applying different “levels of evidence” criteria on conclusions of Cochrane reviews of interventions for low back pain.
J Clin Epidemiol.
2002;
55
1126-1129
15
Lindena G, Diener H C, Hildebrandt J, Klinger R, Maier C, Schöps P, Tronnier V.
Leitlinien zur Schmerztherapie. Methodische Qualität von Leitlinien zur Therapie von Patienten mit Schmerzen.
Schmerz.
2002;
16
194-204
16
Sindrup S H, Jensen T S.
Effect of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action.
Pain.
1999;
83
389-400
17
Sindrup S H, Jensen T S.
Pharmacologic treatment of pain in polyneuropathy.
Neurology.
2000;
55
915-920
18
Sindrup S H, Jensen T S.
Pharmacotherapy of trigeminal neuralgia.
Clin J Pain.
2002;
18
22-27
19
Goodin D S, Frohman E M, Garmany G P, Halper J, Likosky W H, Lublin F D, Silberberg D H, Stuart W H, Noort S van den.
Disease modifying therapies in multiple sclerosis. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines.
Neurology.
2002;
58
169-178
20
Young W F, Weaver M, Mishra B.
Surgical outcome in patients with coexisting multiple sclerosis and spondylosis.
Acta Neurol Scand.
1999;
100
84-87
21
Bashir K, Cai C Y, Moore T A, Whitaker J N, Hadley M N.
Surgery for cervical spinal cord compression in patients with multiple sclerosis.
Neurosurgery.
2000;
47
637-642
22
Etus V, Akansel G, Ilbay K, Koc K, Ceylan S.
Multiple sclerosis and coexisting intradural extramedullary spinal cord tumor: a case report.
Neurol Sci.
2002;
23
119-122
23
Optic Neuritis Study Group .
The clinical profile of optic neuritis. Experience of the Optic Neuritis Treatment Trial.
Arch Ophthalmol.
1991;
109
1673-1678
24
Haas D C, Kent P F, Friedman D I.
Headache caused by single lesion of multiple sclerosis in the periaqueductal gray area.
Headache.
1993;
33
452-455
25
Feneberg W, Pöllmann W.
Headache in multiple sclerosis - a prospective study using the IHS classification criteria.
J Neurol.
2000;
247, suppl 3
III/179-(Abstract)
26
MS-Therapie Konsensusgruppe MSTKG .
Immunmodulatorische Stufentherapie der Multiplen Sklerose. Neue Aspekte und praktische Umsetzung.
Nervenarzt.
2002;
73
556-563
27
Soyka D.
Trigeminusneuralgie und Multiple Sklerose.
Nervenheilkunde.
1999;
18
522-525
28 Diener H C. Kommission „Leitlinien” der Deutschen Gesellschaft für Neurologie .Leitlinien für Diagnostik und Therapie in der Neurologie. 2. Auflage. Stuttgart: Thieme 2003 Postpunktionelles Syndrom 325-327 Migräne 328-334 Episodischer und chronischer Spannungskopfschmerz 337 - 340 Trigeminusneuralgie 341 - 346 Spastik 388-393
29 DGN Deutsche Gesellschaft für Neurologie .Leitlinien 2003. www.dgn.org
30
Wiffen P, Collins S D, McQuay H, Carroll D, Jadad A, Moore A.
Anticonvulsant drugs for acute and chronic pain.
Cochrane Database Syst Rev.
2000;
3
CD001133
31
Hooge J P, Redekop W K.
Trigeminal neuralgia in multiple sclerosis.
Neurology.
1995;
45
1294-1296
32
Ramsaransing G, Zwanikken C, De Keyser J.
Worsening of symptoms of multiple sclerosis associated with carbamazepine.
BMJ.
2000;
320
1113
33
Leandri M, Lundardi G, Inglese M, Messmer-Uccelli M, Mancardi G L, Gottlieb A. et al .
Lamotrigine in trigeminal neuralgia secondary to multiple sclerosis.
J Neurol.
2000;
247
556-558
34
Zakrzewska J M, Patsalos P N.
Oxcarbazepine: a new drug in the management of intractable trigeminal neuralgia.
J Neurol Neurosurg Psychiatry.
1989;
52
472-476
35
Carrazana E, Mikoshiba I.
Rationale and evidence for the use of oxcarbazepine in neuropathic pain.
J Pain Symptom Manage.
2003;
25 (5 Suppl)
S31-S35
36
Schmidt D, Elger C E.
Worin unterscheidet sich Oxcarbazepin von Carbamazepin?.
Nervenarzt.
2004;
75
153-160
37
Backonja M M.
Use of anticonvulsants for treatment of neuropathic pain.
Neurology.
2002;
59 suppl. 2
S14-S17
38
Solaro C, Lunardi G L, Capello E, Inglese M, Messmer Uccelli M, Uccelli A. et al .
An open-label trial of gabapentin treatment of paroxysmal symptoms in multiple sclerosis patients.
Neurology.
1998;
51
609-611
39
Solaro C, Messmer Uccelli M, Uccelli A, Leandri M, Mancardi G L.
Low-dose gabapentin combined with either lamotrigine or carbamazepine can be useful therapies for trigeminal neuralgia in multiple sclerosis.
Eur Neurol.
2000;
44
45-48
40
Khan O A.
Gabapentin relieves trigeminal neuralgia in multiple sclerosis patients.
Neurology.
1998;
51
611-614
41
Zakrzewska J M, Chaudhry Z, Nurmikko T J, Patton D W, Mullens E L.
Lamotrigine (lamictal) in refractory trigeminal neuralgia: results from a double-blind placebo controlled crossover trial.
Pain.
1997;
73
223-230
42
Lunardi G, Leandri M, Albano C, Cultrera S, Fracassi M, Rubino V. et al .
Clinical effectiveness of lamotrigine and plasma levels in essential and symptomatic trigeminal neuralgia.
Neurology.
1997;
48
1714-1717
43
Lüttmann R J, Brinkmann B, Loddenkemper T, Frese A, Bethke F, Husstedt I W, Evers S.
Misoprostol in the treatment of trigeminal neuralgia in MS patients: a report of three cases.
Cephalalgia.
2000;
20
382
44
Reder A T, Arnason B G.
Trigeminal neuralgia in multiple sclerosis relieved by a prostaglandin E analogue.
Neurology.
1995;
45
1097-1100
45
DMKG Study Group .
Misoprostol in the treatment of trigeminal neuralgia associated with multiple sclerosis.
J Neurol.
2003;
250
542-545
46
Fromm G H, Terrence C F, Chattha A S.
Baclofen in the treatment of trigeminal neuralgia: double-blind study and long-term follow-up.
Ann Neurol.
1984;
15
240-244
47
Parmar B S, Shah K H, Gandhi I C.
Baclofen in trigeminal neuralgia - a clinical trial.
Indian J Dent Res.
1989;
1
109-113
48
Steardo L, Leo A, Marano E.
Efficacy of baclofen in trigeminal neuralgia and some other painful conditions. A clinical trial.
Eur Neurol.
1984;
23
51-55
49
Zvartau-Hind M, Din M U, Gilani A, Lisak R P, Khan O A.
Topiramate relieves refractory trigeminal neuralgia in MS patients.
Neurology.
2000;
55
1587-1588
50
Solaro C, Uccelli M M, Brichetto G, Gaspperini C, Mancardi G.
Topiramate relieves idiopathic and symptomatic trigeminal neuralgia.
J Pain Symptom Manage.
2001;
21
367-368
51
Gilron I, Booher S L, Rowan J S, Max M B.
Topiramate in trigeminal neuralgia: a randomized, placebo-controlled multiple crossover pilot study.
Clin Neuropharmacol.
2001;
24
109-112
52
D'Aleo G, Sessa E, di Bella P, Rifici C, Restivo D A, Bramanti P.
Topiramate modulation of R3 nociceptive reflex in multiple sclerosis patients suffering paroxysmal symptoms.
J Neurol.
2001;
248
996-999
53
Chandra B.
The use of clonazepam in the treatment of tic douloureux (a preliminary report).
Proc Aust Assoc Neurol.
1976;
13
119-122
54
Fusco B M, Alessandri M.
Analgesic effect of capsaicin in idiopathic trigeminal neuralgia.
Anesth Analg.
1992;
74
375-377
55
Lechin F, Dijs B van der, Lechin M E, Amat J, Lechin A E, Cabrera A. et al .
Pimozide therapy for trigeminal neuralgia.
Arch Neurol.
1989;
46
960-963
56
Peiris J B, Perera G L, Devendra S V, Lionel N D.
Sodium valproate in trigeminal neuralgia.
Med J Aust.
1980;
2
278
57 Paulus W, Evers S, May A, Steude U, Wolowski A, Pfaffenrath V. DMKG .Therapie und Prophylaxe von Gesichtsneuralgien und anderen Formen der Gesichtsschmerzen. Überarbeitete Therapieempfehlungen der Deutschen Migräne- und Kopfschmerzgesellschaft. Schmerz 2003 Jan; 17 (1): 74-91 www.dmkg.de
58
Berk C, Constantoyannis C, Honey C R.
The treatment of trigeminal neuralgia in patients with multiple sclerosis using percutaneous radiofrequency rhizotomy.
Can J Neurol Sci.
2003;
30
220-223
59
Kondziolka D, Lunsford L D, Bissonette D J.
Long-term results after glycerol rhizotomy for multiple sclerosis-related trigeminal neuralgia.
Can J Neurol Sci.
1994;
21
137-140
60
Broggi G, Ferroli P, Franzini A, Pluderi M, La Mantia L, Milanese C.
Role of microvascular decompression in trigeminal neuralgia and multiple sclerosis.
Lancet.
1999;
354
1878-1879
61
Broggi G, Ferroli P, Franzini A, Servello D, Dones I.
Microvascular decompression for trigeminal neuralgia: comments on a series of 250 cases, including 10 patients with multiple sclerosis.
J Neurol Neurosurg Psychiatry.
2000;
68
59-64
62
Kondziolka D, Lunsford L, Flickinger J.
Stereotactic radiosurgery for the treatment of trigeminal neuralgia.
Clin J Pain.
2002;
18
42-47
63
Huang E, Teh B S, Zeck O, Woo S Y, Lu H H, Chiu J K, Butler E B, Gormley W B, Carpenter L S.
Gamma knife radiosurgery for treatment of trigeminal neuralgia in multiple sclerosis patients.
Stereotact Funct Neurosurg.
2002;
79 (1)
44-50
64
Minagar A, Sheremata W A.
Glossopharyngeal neuralgia and MS.
Neurology.
2000;
54
1368-1370
65
Garcia-Callejo F J, Velert-Vila M M, Talamantes-Escriba F, Blay-Galaud L.
Clinical response of gabapentin for glossopharyngeal neuralgia.
Rev Neurol.
1999;
28 (4)
380-384
66
Espir M L, Millac P.
Treatment of paroxysmal disorders in multiple sclerosis with carbamazepine (Tegretol).
J Neurol Neurosurg Psychiatry.
1970;
33
528-531
67
Twomey J A, Espir M LE.
Paroxysmal symptoms as the first manifestations of multiple sclerosis.
J Neurol Neurosurg Psychiatry.
1980;
43
296-304
68
Cianchetti C, Zuddas A, Randazzo A P, Perra L, Marossu M G.
Lamotrigine adjunctive therapy in painful phenomena in MS: Preliminary observations.
Neurology.
1999;
53
433
69
Voiculescu V, Pruskauer-Apostol B, Alecu C.
Treatment with acetazolamide of brain-stem and spinal paroxysmal disturbances in multiple sclerosis.
J Neurol Neurosurg Psychiatry.
1975;
38
191-193
70
Blakeley J, Jankovic J.
Secondary paroxysmal dyskinesias.
Mov Disord.
2002;
17
726-734
71
Shibasaki H, Kuroiwa Y.
Painful tonic seizures in multiple sclerosis.
Arch Neurol.
1974;
30
47-51
72
Spissu A, Cannas A, Ferrigno P, Pelaghi A E, Spissu M.
Anatomic correlates of painful tonic spasms in multiple sclerosis.
Mov Disord.
1999;
14
331-335
73
Libenson M H, Stafstrom C E, Rosman N P.
Tonic “seizures” in a patient with brainstem demyelination. A MRI study of brain and spinal cord.
Pediatr Neurol.
1994;
11
258-262
74
Kuroiwa Y, Shibasaki H.
Painful tonic seizure in multiple sclerosis. Treatment with diphenylhydantoin and carbamazepine.
Folia Pychiatr Neurol Jap.
1968;
22
107-119
75
Sakurai M, Kanazawa I.
Positive symptoms in multiple sclerosis: their treatment with sodium channel blockers, lidocaine and mexiletine.
J Neurol Sci.
1999;
162
162-168
76
Okada S, Kinoshita M, Fujioka T, Yoshimura M.
Two cases of multiple sclerosis with painful tonic seizures and dysesthesia ameliorated by the administration of mexiletine.
Jpn J Med.
1991;
30
373-375
77
Galer B S, Harle J, Rowbotham M C.
Response to intravenous lidocaine infusion predicts subsequent response to oral mexiletine: a prospective study.
J Pain Symptom Manage.
1996;
12
161-167
78
Sethi K D, Hess D C, Huffnagle V H, Adams R J.
Acetazolamide treatment of paroxysmal dystonia in central demyelinating disease.
Neurology.
1992;
42
919-921
79
Vermote R, Ketelaer P, Carton H.
Pain in multiple sclerosis patients.
Clin Neurol Neurosurg.
1986;
88
87-92
80
Brochet B, Michel P, Henry P.
Pain complaints in outpatients with multiple sclerosis: description and consequences on disability.
Pain Clinic.
1992;
5
157-164
81
Clifford D B, Trotter J L.
Pain in multiple sclerosis.
Arch Neurol.
1984;
41
1270-1272
82
Moulin D E, Foley K M, Ebers G C.
Pain syndromes in multiple sclerosis.
Neurology.
1988;
38
1830-1834
83 Feneberg W, Meister H, Pöllmann W. Sensibilitätsstörungen und Schmerzen. Kapitel 8. In: Wötzel C, Wehner C, Pöllmann W, König N (Hrsg.). Therapie der Multiplen Sklerose. Ein interdisziplinäres Behandlungskonzept. 2. Auflage München: Pflaum 2000: 132-138
84 Zenz M, Jurna I. eds .Lehrbuch der Schmerztherapie. Stuttgart: Wissenschaftliche Verlagsanstalt 2001: 970
85 Zenz M, Strumpf M, Willweber-Strumpf A. Taschenbuch der Schmerztherapie. 2. Auflage. Stuttgart: Wissenschaftliche Verlagsanstalt 2004: 262
86
Backonja M.
Anticonvulsants for the treatment of neuropathic pain syndromes.
Curr Pain Headache Rep.
2003;
7 (1)
39-42
87
Finnerup N B, Gottrup H, Jensen T S.
Anticonvulsants in central pain.
Expert Opin Pharmacother.
2002;
3
1411-1420
88
Dworkin R H, Backonja M, Rowbotham M C, Allen R R, Argoff C R, Bennett G J, Bushnell M C, Farrar J T, Galer B S, Haythornthwaite J A, Hewitt D J, Loeser J D, Max M B, Saltarelli M, Schmader K E, Stein C, Thompson D, Turk D C, Wallace M S, Watkins L R, Weinstein S M.
Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations.
Arch Neurol.
2003;
60 (11)
1524-1534
89
Houtchens M K, Richert J R, Sami A, Rose J W.
Open label gabapentin treatment for pain in multiple sclerosis.
Mult Scler.
1997;
3
250-253
90
Samkoff L M, Daras M, Tuchman A J, Koppel B S.
Amelioration of refractory dysesthetic limb pain in multiple sclerosis by gabapentin.
Neurology.
1997;
49
304-305
91
Vestergaard K, Andersen G, Gottrup H, Kristensen B T, Jensen T S.
Lamotrigine for central poststroke pain: a randomized controlled trial.
Neurology.
2001;
56
184-190
92
Eisenberg E, Lurie Y, Braker C, Daoud D, Ishay A.
Lamotrigine reduces painful diabetic neuropathy: a randomized, controlled study.
Neurology.
2001;
57 (3)
505-509
93
McCleane G.
Lamotrigine can reduce neurogenic pain associated with multiple sclerosis.
Clin J Pain.
1998;
14
269-270
94
Sabatowski R, Galvez R, Cherry D A, Jacquot F, Vincent E, Maisonobe P, Versavel M. The 1008 - 045 Study Group .
Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial.
Pain.
2004;
109 (1 - 2)
26-35
95
Dworkin R H, Corbin A E, Young Jr J P, Sharma U, LaMoreaux L, Bockbrader H, Garofalo E A, Poole R M.
Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial.
Neurology.
2003;
60 (8)
1274-1283
96
Wallin J, Cui J G, Yakhnitsa V, Schechtmann G, Meyerson B A, Linderoth B.
Gabapentin and pregabalin suppress tactile allodynia and potentiate spinal cord stimulation in a model of neuropathy.
Eur J Pain.
2002;
6 (4)
261-272
97
Mason L, Moore R A, Derry S, Edwards J E, McQuay H J.
Systematic review of topical capsaicin for the treatment of chronic pain.
BMJ.
2004;
328
991-994
98
Davies P S, Galer B S.
Review of lidocaine patch 5 % studies in the treatment of postherpetic neuralgia.
Drugs.
2004;
64 (9)
937-947
99 Baron R. Arzneimittel zur Behandlung neuropathischer Schmerzen. In: Fox JM, Jörg J (eds). Neurologische Pharmakotherapie Stuttgart: Thieme 2004: 453-464
100
Kalman S, Osterberg A, Sorensen J, Boivie J, Bertler A.
Morphine responsiveness in a group of well-defined multiple sclerosis patients: a study with i. v. morphine.
Eur J Pain.
2002;
6
69-80
101
Attal N, Guirimand F, Brasseur L, Gaude V, Chauvin M, Bouhassira D.
Effects of IV morphine in central pain.
Neurology.
2002;
58
554-563
102
Raja S N, Haythornthwaite J A, Pappagallo M, Clark M R, Travison T G, Sabeen S, Royall R M, Max M B.
Opioids versus antidepressants in postherpetic neuralgia: a randomized, placebo-controlled trial.
Neurology.
2002;
59
1015-1021
103
Mattia C, Paoletti F, Coluzzi F, Boanelli A.
New antidepressants in the treatment of neuropathic pain. A review.
Minerva Anestesiol.
2002;
68 (3)
105-114
104
Sindrup S H, Bach F W, Madsen C, Gram L F, Jensen T S.
Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial.
Neurology.
2003;
60
1284-1289
105
Schüler P, Seibel K, Chevts V, Schaffler K.
Analgetische Wirkung des selektiven Noradrenalin-Wiederaufnahme-Hemmers Reboxetin.
Nervenarzt.
2002;
73 (2)
149-154
106
Wade D T, Robson P, House H, Makela P, Aram J.
A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms.
Clin Rehabil.
2003;
17
21-29
107
Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, Thompson A. UK MS Research Group .
Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial.
Lancet.
2003;
362 (9395)
1517-1526
108
Hocking G, Cousins M J.
Ketamine in chronic pain management: an evidence-based review.
Anesth Analg.
2003;
97
1730-1739
109
Sjölund B H.
Pain and rehabilitation after spinal cord injury: the case of sensory spasticity?.
Brain Res Brain Res Rev.
2002;
40 (1 - 3)
250-256
110
Eide P K, Jorum E, Stubhaug A, Bremnes J, Breivik H.
Relief of post-herpetic neuralgia with the N-methyl-D-aspartic acid receptor antagonist ketamine: a double-blind, cross-over comparison with morphine and placebo.
Pain.
1994;
58 (3)
347-354
111
Chiba S, Ito M, Matsumoto H.
Amantadine treatment for refractory pain and fatigue in patients with multiple sclerosis.
Can J Neurol Sci.
1992;
19
309
112
Otto M, Bach F W, Jensen T S, Sindrup S H.
Valproic acid has no effect on pain in polyneuropathy: a randomized, controlled trial.
Neurology.
2004;
62
285-288
113
Herman R M, D'Luzansky S C, Ippolito R.
Intrathecal baclofen suppresses central pain in patients with spinal lesions. A pilot study.
Clin J Pain.
1992;
8
338-345
114
Becker R, Uhle E I, Alberti O, Bertalanffy H.
Continuous intrathecal baclofen infusion in the management of central deafferentation pain.
J Pain Symptom Manage.
2000;
20
313-315
115
Paice J A, Penn R D, Kroin J S.
Intrathecal octreotide for relief of intractable nonmalignant pain: 5-year experience with two cases.
Neurosurgery.
1996;
38
203-207
116
Harke H, Rosenow E, Tronnier V, Fromme C, Deynet G, Gretenkort P, Buschmann D, Rohr P, Ladleif H U, Glinski E von, Schutze G, Schultze R, Keller H L, Kniesel B, Pfeifer R, Lux E.
Standardisierung invasiver neuromodulativer Verfahren.
Schmerz.
2003;
17(1)
44-49
117
Nix W A.
Was ist gesichert in der Schmerztherapie? Haben Neuroleptika eine analgetische Potenz? Eine Metaanalyse.
Schmerz.
1998;
12
30-38
118 Jurna I, Motsch J. Nichtanalgetika: Antidepressiva, Antikonvulsiva, Neuroleptika, Tranquillantien und zentrale Muskelrelaxantien, Clonidin, Cortison. Kapitel 3. In: Zenz M, Jurna I. Lehrbuch der Schmerztherapie Stuttgart: Wissenschaftliche Verlagsanstalt 2001: 281-293
119
Graff-Radford S B, Shaw L R, Naliboff B N.
Amitriptyline and fluphenazine in the treatment of postherpetic neuralgia.
Clin J Pain.
2000;
16
188-192
120
Ehde D M, Jensen M P, Engel J M, Turner J A, Hoffmann A J, Carden D D.
Chronic pain secondary to disability: a review.
Clin J Pain.
2003;
19
3-17
121
Schayck R H van, Weiller C.
Behandlung akuter und chronischer Schmerzen in der neurologischen Rehabilitation (Teil I).
Neurol Rehabil.
2002;
8
1-17
122 Pöllmann W, Albrecht H, Wötzel C, König N H. Physiotherapie bei Multipler Sklerose. In: Zettl UK, Mix E (Hrsg.). Multiple Sklerose. Kausalorientierte, symptomatische und rehabilitative Therapie Berlin: Springer 2001: 293-305
123
Klewer J, Pöhlau D, Nippert I, Haas J, Kugler J.
Problems reported by elderly patients with multiple sclerosis.
J Neurosci Nurs.
2001;
33
167-171
124 Wötzel C, Wehner C, Pöllmann W, König N. Therapie der Multiplen Sklerose. Ein interdisziplinäres Behandlungskonzept. 2. Auflage. München: Pflaum 2000
125
Sachais B A, Logue J N, Carey M S.
Baclofen, a new antispastic drug. A controlled, multicenter trial in patients with multiple sclerosis.
Arch Neurol.
1977;
34
422-428
126
Ward A B, Kadies M.
The management of pain in spasticity.
Disabil Rehabil.
2002;
24
443-453
127
Shakespeare D, Boggild M, Young C.
Anti-spasticity agents for multiple sclerosis.
Cochrane Database Syst Rev.
2003;
4
CD001332
128
Mueller M E, Gruenthal M, Olson W L, Olson W H.
Gabapentin for relief of upper motor neuron symptoms in multiple sclerosis.
Arch Phys Med Rehabil.
1997;
78
521-524
129
Solaro C, Uccelli M M, Guglieri P, Uccelli A, Mancardi G L.
Gabapentin is effective in treating nocturnal painful spasms in multiple sclerosis.
Mult Scler.
2000;
6
192-193
130
Cutter N C, Scott D D, Johnson J C, Whiteneck G.
Gabapentin effect on spasticity in multiple sclerosis: a placebo-controlled, randomised trial.
Arch Phys Med Rehabil.
2000;
81
164-169
131
Schapiro R T.
Management of spasticity, pain, and paroysmal phenomena in multiple sclerosis.
Curr Neurol Neurosci Reports.
2001;
1
299-302
132
Hawker K, Frohman E, Racke M.
Levetiracetam for phasic spasticity in multiple sclerosis.
Arch Neurol.
2003;
60
1772-1774
133
Lang A M.
Botulinum toxin type A therapy in chronic pain disorders.
Arch Phys Med Rehabil.
2003;
84 (3 Suppl 1)
S69-73
134
Göbel H, Jost W H.
Botulinum toxin in specific pain therapy.
Schmerz.
2003;
17
149-165
135
Wissel J, Muller J, Dressnandt J, Heinen F, Naumann M, Topka H, Poewe W.
Management of spasticity associated pain with botulinum toxin A.
J Pain Symptom Manage.
2000;
20
44-49
136
Chalkiadaki A, Rohr U P, Hefter H.
Frühe Schmerzreduktion in der Therapie von Spastik nach einmaliger Botulinustoxin-A-Injektion.
Dtsch Med Wochenschr.
2001;
126
1361-1364
137
Dario A, Scamoni C, Bono G, Ghezzi A, Zaffaroni M.
Functional improvement in patients with severe spinal spasticity treated with chronic intrathecal baclofen infusion.
Funct Neurol.
2001;
16
311-315
138
Middel B, Kuipers-Upmeijer H, Bouma J, Staal M. et al .
Effect of intrathecal baclofen delivered by an implanted programmable pump on health-related quality of life in patients with severe spasticity.
J Neurol Neurosurg Psychiatry.
1997;
63
204-209
139
Ochs A, Tonn J C.
Functional outcome and clinical significance of long-term intrathecal baclofen therapy for severe spasticity.
J Neuro Rehab.
1996;
10
159-166
140
Dahm P O, Nitescu P V, Appelgren L K, Curelaru I I.
Long-term intrathecal (i. t.) infusion of bupivacaine relieved intractable pain and spasticity in a patient with multiple sclerosis.
Eur J Pain.
1998;
2
81-85
141
Jarrett L, Nandi P, Thompson A J.
Managing severe lower limb spasticity in multiple sclerosis: does intrathecal phenol have a role?.
J Neurol Neurosurg Psychiatry.
2002;
73
705-709
142
Heun R, Emser W, Schimrigk K.
Evozierte Potenziale unter intrathekaler und systemischer Kortikosteroid-Therapie bei Multipler Sklerose.
Z EEG-EMG.
1987;
20
88-91
143
Hoffmann V, Schimrigk S, Islamova S, Hellwig K, Lukas C, Brune N, Pöhlau D, Przuntek H, Muller T.
Efficacy and safety of repeated intrathecal triamcinolone acetonide application in progressive multiple sclerosis patients.
J Neurol Sci.
2003;
211
81-84
144
Salame K, Ouaknine G E, Rochkind S, Constantini S, Razon N.
Surgical treatment of spasticity by selective posterior rhizotomy: 30 years experience.
Isr Med Assoc J.
2003;
5 (8)
543-546
145
Philadelphia Panel .
Philadelphia Panel evidence-based clinical practice guidelines on selected rehabilitation interventions for neck pain.
Phys Ther.
2001;
81
1701-1717
146
Philadelphia Panel .
Philadelphia Panel evidence-based clinical practice guidelines on selected rehabilitation interventions for shoulder pain.
Phys Ther.
2001;
81
1719-1730
147
Philadelphia Panel .
Philadelphia Panel evidence-based clinical practice guidelines on selected rehabilitation interventions for knee pain.
Phys Ther.
2001;
81
1675-1700
148
Feine J S, Lund J P.
An assessment of the efficacy of physical therapy and physical modalities for the control of chronic musculoskeletal pain.
Pain.
1997;
71
5-23
149
Korthals de Bos I B, Hoving J L, Tulder M W van, Rutten van Molken M P, Ader H J, de Vet H C, Koes B W, Vondeling H, Bouter L M.
Cost effectiveness of physiotherapy, manual therapy, and general practitioner care for neck pain: economic evaluation alongside a randomised controlled trial.
BMJ.
2003;
326
911
150
Price C I.
Shoulder pain after stroke: a research challenge.
Age Ageing.
2002;
31 Suppl 3
36-38
151
Turner-Stokes L, Jackson D.
Shoulder pain after stroke: a review of the evidence base to inform the development of an integrated care pathway.
Clin Rehabil.
2002;
16
276-298
152 Arzneimittelkommision der deutschen Ärzteschaft .Degenerative Gelenkerkrankungen. Therapieempfehlungen der AKDAE, 2. Auflage. 2001 www.akdae.de
153
Eccles M, Freemantle N, Mason J.
North of England evidence based guideline development project: summary guideline for non-steroidal anti-inflammatory drugs versus basic analgesia in treating the pain of degenerative arthritis. The North of England Non-Steroidal Anti-Inflammatory Drug Guideline Development Group.
BMJ.
1998;
317
526-530
154
Schnitzer T J. American College of Rheumatology .
Update of ACR guidelines for osteoarthritis: role of the coxibs.
J Pain Symptom Manage.
2002;
23 (4 Suppl)
S24-30
155
Towheed T E, Judd M J, Hochberg M C, Wells G.
Acetaminophen for osteoarthritis.
Cochrane Database Syst Rev.
2003;
(2)
CD004257
156
Roth S H.
A new role for opioids in the treatment of arthritis.
Drugs.
2002;
62
255-263
157
Sheean G.
Botulinum toxin for the treatment of musculoskeletal pain and spasm.
Curr Pain Headache Rep.
2002;
6
460-469
158
American Geriatrics Society .
Exercise prescription for older adults with osteoarthritis pain: Consensus practice recommendations.
J Am Geriatr Soc.
2001;
49
808-823
159
Albrecht H, Pöllmann W, König N.
Akute Fußheberparese bei multipler Sklerose.
Nervenarzt.
1996;
67
163-169
160 Feneberg W. Blasenstörungen bei Multipler Sklerose. MSTKG-Konsensusgruppe Symptomatische Therapie 2004
161
Neilley L K, Goodin D S, Goodkin D E, Hauser S L.
Side effect profile of interferon beta-1b in MS: results of an open label trial.
Neurology.
1996;
46
552-554
162
Reess J, Haas J, Gabriel K, Fuhlrott A, Fiola M.
Both paracetamol and ibuprofen are equally effective in managing flu-like symptoms in relapsing-remitting multiple sclerosis patients during interferon beta-1a (AVONEX) therapy.
Multiple Sclerosis.
2002;
8
15-18
163
Walther E U, Dang T, Hohlfeld R.
Management of side-effects of beta-interferon therapy in MS.
Int MSJ.
1999;
5
65-70
164
Pöllmann W, Erasmus L-P, Feneberg W, Then Bergh F, Straube A.
Interferon beta but not glatiramer acetate therapy aggravates headaches in MS.
Neurology.
2002;
59
636-639
165
Dalakas M C.
Intravenous immune globulin therapy for neurologic diseases.
Ann Intern Med.
1997;
126
721-730
166
Finkel A G, Howard J F, Mann J D.
Successful treatment of headache related to intravenous immunglobulin with antimigraine medication.
Headache.
1998;
38
317-321
167
Evans R W, Armon C, Frohman E M, Goodin D S.
Assessment: prevention of post-lumbar puncture headaches: report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology.
Neurology.
2000;
55
909-914
168
Samanta J, Kendall J, Samanta A.
10-minute consultation: chronic low back pain.
BMJ.
2003;
326
535
169
Philadelphia Panel .
Philadelphia Panel evidence-based clinical practice guidelines on selected rehabilitation interventions for low back pain.
Phys Ther.
2001;
81
1641-1674
170 Tulder M W van, Malmivaara A, Esmail R, Koes B W. Exercise therapy for low back pain (Cochrane Methodology Review). In: The Cochrane Library, Issue 4. 2003 Chichester, UK: John Wiley & Sons, Ltd.
171
Furlan A D, Brosseau L, Imamura M, Irvin E.
Massage for low back pain.
Cochrane Database Syst Rev..
2002;
(2)
CD001929
172
Gadsby J G, Flowerdew M W.
Transcutaneous electrical nerve stimulation and acupuncture-like transcutaneous electrical nerve stimulation for chronic low back pain.
Cochrane Database Syst Rev.
2000;
(2)
CD000210
173
Milne S, Welch V, Brosseau L, Saginur M, Shea B, Tugwell P, Wells G.
Transcutaneous electrical nerve stimulation (TENS) for chronic low back pain.
Cochrane Database Syst Rev.
2001;
(2)
CD003008
174
Brosseau L, Milne S, Robinson V, Marchand S, Shea B, Wells G, Tugwell P.
Efficacy of the transcutaneous electrical nerve stimulation for the treatment of chronic low back pain: a meta-analysis.
Spine.
2002;
27
596-603
175
Al-Smadi J, Warke K, Wilson I, Cramp A F, Noble G, Walsh D M, Lowe-Strong A S.
A pilot investigation of the hypoalgesic effects of transcutaneous electrical nerve stimulation upon low back pain in people with multiple sclerosis.
Clin Rehabil.
2003;
17
742-749
176
Leibing E, Leonhardt U, Koster G, Goerlitz A, Rosenfeldt J A, Hilgers R, Ramadori G.
Acupuncture treatment of chronic low-back pain - a randomized, blinded, placebo-controlled trial with 9-month follow-up.
Pain.
2002;
96
189-196
177 Arzneimittelkommission der deutschen Ärzteschaft .Kreuzschmerzen. Therapieempfehlungen der AKDAE, 2. Auflage. 2000 www.akdae.de
178 Tulder M W van, Scholten R JPM, Koes B W, Deyo R A. Non-steroidal anti-inflammatory drugs for low back pain (Cochrane Methodology Review). In: The Cochrane Library, Issue 4. 2003 Chichester, UK: John Wiley & Sons, Ltd.
179
Foster L, Clapp L, Erickson M, Jabbari B.
Botulinum toxin A and chronic low back pain. A randomised, double-blind study.
Neurology.
2001;
56
1290-1293
180
Ramirez-Lassepas M, Tulloch J W, Quinones M R, Snyder B D.
Acute radicular pain as a presenting symptom in multiple sclerosis.
Arch Neurol.
1992;
49
255-258
181
Portenoy R K, Yang K, Thorton D.
Chronic intractable pain: an atypical presentation of multiple sclerosis.
J Neurol.
1988;
235
226-228
182
Gangji V, Appelboom T.
Analgesic effect of intravenous pamidronate on chronic back pain due to osteoporitic vertebral fractures.
Clin Rheumatol.
1999;
18
266-267
183
Goemaere S, Laere M van, De Neve P, Kaufman J M.
Bone mineral status in paraplegic patients who do or do not perform standing.
Osteoporos Int.
1994;
4
138-143
184
Göbel H, Petersen-Braun M, Soyka D.
The epidemiology of headache in Germany: a nationwide survey of a representative sample on the basis of the headache classification of the International Headache Society.
Cephalalgia.
1994;
14
97-106
185
Headache Classification Committee of the International Headache Society .
Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain.
Cephalalgia.
1988;
8, suppl. 7
1-96
Klassifikation und diagnostische Kriterien für Kopfschmerzerkrankungen, Kopfneuralgien und Gesichtsschmerz.
Nervenheilkunde.
1989;
8
161-203
186
Rasmussen B K.
Epidemiology of headache.
Cephalalgia.
1995;
15
45-68
187
Lampl C, Buzath A, Baumhackl U, Klingler D.
One-year prevalence of migraine in Austria: a nation-wide survey.
Cephalalgia.
2003;
23
280-286
188
Freedman M S, Gray T A.
Vascular headache: a presenting symptom of multiple sclerosis.
Can J Neurol Sci.
1989;
16
63-66
189
Frese A, Friedrich H, Poehlau D, Schimrigk S, Bethke F, Lüttmann R J, Husstedt I W, Evers S.
The prevalence of migraine in multiple sclerosis patients.
Cephalalgia.
2001;
21
317-317 (abstract)
190
Weiller C, May A, Limmroth V, Juptner M, Kaube H, Schayck R V, Coenen H H, Diener H C.
Brain stem activation in spontaneous human migraine attacks.
Nature Med.
1995;
1 (7)
658-660
191 Deutsche Migräne und Kopfschmerzgesellschaft .www.dmkg.de
Dr. Walter Pöllmann
Marianne Strauß-Klinik
Milchberg 21
82335 Berg ·
Email: walter.poellmann@ms-klinik.info